The role of the Scientific Advisory Board is to enable effective review of the strategic approach and work performed by the Consortium, as well as to challenge and improve the project to maximise its impact and enable it to meet its objectives.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
